<?xml version='1.0' encoding='UTF-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN" "JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
  <front>
    <journal-meta id="journal-meta-1">
      <journal-id journal-id-type="nlm-ta"> Journal of Current Medical Research and Opinion</journal-id>
      <journal-id journal-id-type="publisher-id"> Journal of Current Medical Research and Opinion</journal-id>
      <journal-id journal-id-type="journal_submission_guidelines">http://cmro.in/index.php/jcmro/index</journal-id>
      <journal-title-group>
        <journal-title> Journal of Current Medical Research and Opinion</journal-title>
      </journal-title-group>
      <issn publication-format="print">2589-8779</issn>
    </journal-meta>
    <article-meta id="article-meta-1">
      <article-id pub-id-type="doi">https://doi.org/10.15520/jcmro.v3i09.337</article-id>
      <article-categories>
        <subj-group>
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title id="at-9c2991d26afc">A Short Review on OSMF: Oral Sub mucous Fibrosis</article-title>
        <alt-title alt-title-type="right-running-head">A Short Review on OSMF: Oral Sub mucous Fibrosis</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid"/>
          <name id="n-392d2fc2802b">
            <surname>Thakur</surname>
            <given-names>Dr. Vishal</given-names>
          </name>
          <email>doctorvishal10@gmail.com</email>
          <xref id="x-32a64c189f28" rid="a-c22633152491" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid"/>
          <name id="n-0027916fa092">
            <surname>Jassal</surname>
            <given-names>Dr. Supriya</given-names>
          </name>
          <xref id="x-0b15f790b028" rid="a-d91fd350836f" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid"/>
          <name id="n-8b70f688306c">
            <surname>Kumar</surname>
            <given-names>Dr. Atul</given-names>
          </name>
          <xref id="x-2f0bd4ab9fc0" rid="a-ca2043850494" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid"/>
          <name id="n-7aab078282e8">
            <surname>Sharma</surname>
            <given-names>Dr. Pallavi</given-names>
          </name>
          <xref id="x-c376a90c9dce" rid="a-85f98e34f936" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid"/>
          <name id="n-d9c8678b161c">
            <surname>Sahi</surname>
            <given-names>Dr. Shivangi</given-names>
          </name>
          <xref id="x-875fe1d8cbdc" rid="a-3d8bf2122b18" ref-type="aff">5</xref>
        </contrib>
        <aff id="a-c22633152491">
          <institution>Dental Surgery (HPU Shimla) , Ekdant Dental Clinic (H.P.)</institution>
        </aff>
        <aff id="a-d91fd350836f">
          <institution>BDS , Bhojia Dental College ,Baddi , H.P. </institution>
        </aff>
        <aff id="a-ca2043850494">
          <institution>BDS (HPU Shimla), Dental surgeon, Ident idyll dental care (Jammu)</institution>
        </aff>
        <aff id="a-85f98e34f936">
          <institution>BDS (HPU Shimla)</institution>
        </aff>
        <aff id="a-3d8bf2122b18">
          <institution>BDS , Govt. Dental College  Shimla</institution>
        </aff>
      </contrib-group>
      <fpage>619</fpage>
      <permissions>
        <copyright-year>2020</copyright-year>
      </permissions>
      <abstract id="abstract-10ef2f76b4df">
        <title id="abstract-title-94bac282350e">Abstract</title>
        <p id="paragraph-33d31a5809ef">Oral submucous fibrosis (OSMF) is a premalignant condition caused by betel chewing. OSMF is a premalignant condition that can lead to oral cancer. A risk that is further increased by concomitant tobacco consumption. OSMF is a diagnosis based on clinical symptoms and confirmation by histopathology. Major constituents of betel quid are arecoline from betel nuts and copper, which are responsible for fibroblast dysfunction and fibrotic band formation. Drug therapy include antifibrotic, anti-inflammatory, and antioxidants, homemade remedies including turmeric and tulsi . Prevention is most important in case of OSMF , because severe cases of OSMF are irreversible.</p>
        <p id="p-6c7830075b96"> </p>
      </abstract>
      <kwd-group id="kwd-group-1">
        <title>Keywords</title>
        <kwd>OSMF</kwd>
        <kwd>betel</kwd>
        <kwd>oral disease</kwd>
        <kwd>oral cancer</kwd>
        <kwd>tobacco</kwd>
        <kwd>fibrosis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title id="t-9e0e34355533">Introduction:</title>
      <p id="t-ae7aee4370e7">Oral submucous fibrosis is a chronic disease affecting the oral mucosa, as well as the pharynx and the upper two-thirds of the esophagus. There is substantial evidence that lends support to a critical role of areca nuts in the etiology behind oral submucous fibrosis <xref id="x-f47631ee3957" rid="R87116520196348" ref-type="bibr">1</xref><bold id="strong-1">.</bold> It is complex condition of the oral cavity. In simple word patients jaw become rigid to the point that he/she is unable to open mouth.This is common oral cavity problem among south Asian problem strongly associate with the practice of chewing areca nut and betel quid. People who have strong habit of chewing Pan, Pan Masala, Gutka, Mawa and Mainpuri tobacco have strong chances of having OSMF. Patients with OSMF have complaint of reduced mouth opening.</p>
      <p id="p-d1435a8f1d9e"><bold id="strong-2">Background</bold>: In 1952, Schwartz coined the term atrophica idiopathica mucosa oris to describe an oral fibrosing disease he discovered in 5 Indian women from Kenya <xref id="x-caefbf8e6d99" rid="R87116520196349" ref-type="bibr">2</xref>. Joshi subsequently coined the termed oral submucous fibrosis (OSF) for the condition in 1953 <xref id="x-864271bcebea" rid="R87116520196350" ref-type="bibr">3</xref>. Oral submucous fibrosis is a chronic debilitating disease of the oral cavity characterized by inflammation and progressive fibrosis of the submucosal tissues (lamina propria and deeper connective tissues). Oral submucous fibrosis results in marked rigidity and an eventual inability to open the mouth. <xref id="x-9a0f2316dbbe" rid="R87116520196351" ref-type="bibr">4</xref> The buccal mucosa is the most commonly involved site, but any part of the oral cavity can be involved, even the pharynx. </p>
      <p id="p-6108acabed18"><bold id="strong-3">Etiology &amp; Pathogenesis: </bold>The pathogenesis of the disease is not well established, but the cause of oral submucous fibrosis is believed to be multifactorial. Factors include areca nut chewing, ingestion of chilies, genetic and immunologic processes, nutritional deficiencies, and other factors.</p>
      <p id="p-55f096e2cee4">Previous studies on the pathogenesis of OSF have suggested that the occurrence may be due to:</p>
      <p id="p-fd08ac82686e">-Clonal selection of fibroblasts with a high amount of collagen production during the long-term exposure to areca quid ingredients <xref id="x-992d0b803d7e" rid="R87116520196352" ref-type="bibr">5</xref> </p>
      <p id="p-e614508080e6">-Stimulation of fibroblast proliferation and collagen synthesis by arecanut alkaloids <xref id="x-9dee82b135fe" rid="R87116520196353" ref-type="bibr">6</xref></p>
      <p id="p-1b79592c1f2a">-By decreased secretion of collagenase <xref id="x-24a9bd12cf86" rid="R87116520196354" ref-type="bibr">7</xref></p>
      <p id="paragraph-8">- And by an increase in collagen cross-linkage as caused by upregulation of lysyl oxidase by OSF fibroblasts  <xref id="x-9399bc495ad5" rid="R87116520196355" ref-type="bibr">8</xref></p>
      <p id="paragraph-9">-Smoking and alcohol consumption alone, habits common to areca nut chewers, have been found to have no effect in the development of oral submucous fibrosis ,but their addition to areca nut chewing can be a risk for oral submucous fibrosis .<xref id="x-315eb4559508" rid="R87116520196356" ref-type="bibr">9</xref> </p>
      <p id="paragraph-10">- A genetic component is assumed to be involved in OSF Patients with increased frequency of HLA-A10, HLA-B7, and HLA-DR3 reported in people without a history of betel nut chewing or chili ingestion. <xref rid="R87116520196357" ref-type="bibr">10</xref>, <xref rid="R87116520196358" ref-type="bibr">11</xref> </p>
      <p id="paragraph-11">- Iron deficiency anemia, vitamin B complex deficiency and malnutrition are promoting factors that derange the repair of the inflamed oral mucosa, leading to defective healing and resultant scarring <xref id="x-3c20b7dcc21e" rid="R87116520196357" ref-type="bibr">10</xref> </p>
      <p id="paragraph-12"><bold id="strong-4">Histopathology : </bold>Microscopically, the principal feature is atrophy of the epithelium<bold id="strong-5"> </bold> and subjacent fibrosis  <xref id="x-7f37f69cb8ec" rid="f-944f19339c96" ref-type="fig">Figure 1</xref> <xref id="x-861fe5638b49" rid="R87116520196359" ref-type="bibr">12</xref>. Epithelial dysplasia<bold id="strong-6"> </bold> occasionally may be evident. The lamina propria is poorly<bold id="strong-7"> </bold> vascularized and hyalinized; fibroblasts are few. A diffuse mild<bold id="strong-8"> </bold> to moderate inflammatory infiltrate is present. Type I collagen<bold id="strong-9"> </bold> predominates in the submucosa, whereas type III collagen<bold id="strong-10"> </bold> tends to localize at the epithelium–connective tissue interfaceand around blood vessels, salivary glands, and muscle.<xref id="x-e03fc731339b" rid="R87116520196359" ref-type="bibr">12</xref> <bold id="strong-11"/></p>
      <p id="p-1f3152a54457"/>
      <fig id="f-944f19339c96" position="anchor" orientation="portrait" fig-type="graphic">
        <label>Figure 1 </label>
        <caption id="c-c3338f9146b9">
          <title id="t-bc2edf8838eb">Submucous fibrosis showing epithelial atrophy over fibroticsubmucosa. <xref id="x-e08c45b82764" rid="R87116520196359" ref-type="bibr">12</xref> </title>
        </caption>
        <graphic id="g-e9365bfec663" xlink:href="https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/dd18904f-f92f-4f46-a3f8-86d4e89b0ed4/image/f8da4abb-edac-4268-826b-cbfd1ff9aabc-uimage.png"/>
      </fig>
      <p id="p-d0eecc69ca16"/>
      <p id="p-295791bcb3f0"><bold id="s-96a4866fe274">Epidemiology: </bold>Areca nut–derived products are commonly used by several<bold id="s-11269f464265"> </bold> hundred million individuals in the southern parts of<bold id="s-45b3ee8d6a20"> </bold> Asia. Oral complications are most commonly<bold id="s-08ad3c4b899a"> </bold> observed on the lips, buccal mucosa, retromolar area, and soft<bold id="s-492597b219cc"> </bold> palatal mucosa. The habit of chewing betel quid, containing<bold id="s-168315f94d55"> </bold> fresh, dried, or cured areca nut, and flavoring ingredients<bold id="s-7e4802dea53b"> </bold> is widespread in India, Pakistan, Bangladesh, and Sri Lanka<bold id="s-45564c6a4481"> </bold> and in immigrants coming from these regions. Tobacco is<bold id="s-88bb4b5e126b"> </bold> often used in conjunction with betel quid. The habit is more<bold id="s-7daf9c577b2b"> </bold> common among women in some geographic areas, which is<bold id="s-dfa189f0645b"> </bold> also reflected in the gender distribution of oral submucous<bold id="strong-12"> </bold> fibrosis.<bold id="strong-13"> </bold> The global incidence of oral submucous fibrosis is<bold id="strong-14"> </bold> estimated at 2.5 million individuals. The prevalence in<bold id="strong-15"> </bold> Indian populations is 5% for women and 2% for men.<bold id="strong-16"> </bold> Individuals in less than 20 years old seem to be affected<bold id="strong-17"> </bold> more commonly by oral submucous fibrosis than individuals<bold id="strong-18"> </bold> in other age groups. <xref id="x-e3a9e57faeba" rid="R87116520196348" ref-type="bibr">1</xref> <bold id="strong-19"/></p>
    </sec>
    <sec>
      <title id="t-744224c0e9a6">Clinical Presentation:</title>
      <p id="p-31d0f193969a"> OSMF is seen typically between the ages of 20 and 40 and is often associated with the habitual use of compounds containing areca (betel) nut and tobacco in various forms, including a quid form (paan) and a powdered form (gutka), where these are placed in the oral cavity for extended periods of time and often are replaced up to several times per day. Oral submucous fibrosis presents as a whitish yellow change that has a chronic, insidious biological course. It is characteristically seen in the oral cavity, but on occasion it may extend into the pharynx and the esophagus. Submucous fibrosis occasionally may be associated with vesicle formation. Over time, the affected mucosa, especially the soft palate and the buccal mucosa, loses its resilience and shows limited vascularity and elasticity. This process then progresses from the lamina propria to the underlying musculature. Fibrous bands are readily palpable in the soft palate and the buccal mucosa. The clinical result is significant trismus with considerable difficulty in eating.</p>
      <p id="p-3a2db34467c3">Patient may give you , history of either all or few of these sypmtoms that include –</p>
      <list list-type="order">
        <list-item id="list-item-1">
          <p>Inability to open the mouth (trismus) due to fibrosis</p>
        </list-item>
        <list-item id="list-item-2">
          <p>Pain or burning sensation upon consumption of spicy food stuffs</p>
        </list-item>
        <list-item id="list-item-3">
          <p>Increased salivation</p>
        </list-item>
        <list-item id="list-item-4">
          <p>Change of gustatory sensation</p>
        </list-item>
        <list-item id="list-item-5">
          <p>Hearing loss may occur due to stenosis of the eustachian tubes</p>
        </list-item>
        <list-item id="list-item-6">
          <p>Dryness of the mouth</p>
        </list-item>
        <list-item id="list-item-7">
          <p>Dysphagia to solids (if the esophagus is involved)</p>
        </list-item>
      </list>
    </sec>
    <sec>
      <title id="t-86e6f073a3dd">
        <bold id="strong-21">Classification in OSMF:</bold>
      </title>
      <p id="p-7ce30c439b9b">
        <bold id="s-96430b3a3468">A. According to clinical &amp; physical findings</bold>
      </p>
      <p id="p-e27c3d658fd0"><bold id="strong-22">Stage 1 - </bold>Stomatitis includes erythematous mucosa, vesicles, mucosal ulcers,</p>
      <p id="p-ba81d8347ec9">melanotic mucosal pigmentation, and mucosal petechia. </p>
      <p id="p-1adb23c68613"><bold id="strong-23">Stage 2 - </bold>Fibrosis occurs in ruptured vesicles and ulcers when they heal, which is the hallmark of this stage. Early lesions demonstrate blanching of the oral mucosa.</p>
      <p id="p-eff03f7e1855">Older lesions include vertical and circular palpable fibrous bands in the buccal mucosa and around the mouth opening or lips, resulting in a mottled, marblelike appearance of the mucosa because of the vertical, thick, fibrous bands running in a blanching mucosa. Specific findings include the following:</p>
      <p id="p-50486639bd0a">Reduction of the mouth opening (trismus)</p>
      <p id="p-08611121168a">Stiff and small tongue</p>
      <p id="paragraph-13">Blanched and leathery floor of the mouth</p>
      <p id="paragraph-14">Fibrotic and depigmented gingiva</p>
      <p id="paragraph-15">Rubbery soft palate with decreased mobility</p>
      <p id="paragraph-16">Blanched and atrophic tonsils</p>
      <p id="paragraph-17">Shrunken budlike uvula</p>
      <p id="paragraph-18">Sinking of the cheeks, not commensurate with age or nutritional status.</p>
      <p id="paragraph-19"><bold id="strong-24">Stage 3 </bold>- Sequeal of OSMF includes -</p>
      <p id="paragraph-20">Leukoplakia is precancerous and is found in more than 25% of individuals with OSMF. Speech and hearing deficits may occur because of involvement of the tongue and the eustachian tubes.<xref id="x-c2990db558d0" rid="R87116520196360" ref-type="bibr">13</xref> </p>
      <p id="p-107598820681">
        <bold id="s-65e1dd86fe63">B. According to surgical management of trismus: <xref id="x-255edf122dba" rid="R87116520196361" ref-type="bibr">14</xref> </bold>
      </p>
      <p id="paragraph-21"><bold id="strong-25">Group I:</bold> IT is the earliest stage and is not associated with mouth opening limitations. Patients with an interincisal distance of greater than 35 mm.</p>
      <p id="paragraph-22"><bold id="strong-26">Group II:</bold> Patients with an interincisal distance of 26-35 mm.</p>
      <p id="paragraph-23"><bold id="strong-27">Group III:</bold> These are moderately advanced cases. This stage refers to patients with an interincisal distance of 15-26 mm. Fibrotic bands are visible at the soft palate, and pterygomandibular raphe and anterior pillars of faucets are present.</p>
      <p id="paragraph-24"><bold id="strong-28">Group IVA:</bold> Trismus is severe, with an interincisal distance of less than 15 mm and extensive fibrosis of all the oral mucosa. </p>
      <p id="paragraph-25"><bold id="strong-29">Group IVB:</bold> Disease is most advanced, with premalignant and malignant changes throughout the mucosa. <xref id="x-84415403c14d" rid="R87116520196361" ref-type="bibr">14</xref> </p>
      <p id="p-17392932c14c">
        <bold id="s-dd60922dfbcc">C. Histological Classification in OSMF:<xref id="x-9ea8a1cab48d" rid="R87116520196362" ref-type="bibr">15</xref> <xref id="x-1f8beadc0df7" rid="tw-91b6ba682e4c" ref-type="table">Table 1</xref> </bold>
      </p>
      <table-wrap id="tw-91b6ba682e4c" orientation="portrait">
        <label>Table 1</label>
        <caption id="c-ec9c8cd0e4ed"/>
        <table id="table-1" rules="rows">
          <colgroup/>
          <tbody id="table-section-1">
            <tr id="table-row-1">
              <td id="table-cell-1" align="left">Very early (stage I)</td>
              <td id="table-cell-2" align="left">Early (stage II)</td>
              <td id="table-cell-3" align="left">Moderately advanced (stage III)</td>
              <td id="table-cell-4" align="left">Advanced (stage IV)</td>
            </tr>
            <tr id="table-row-2">
              <td id="table-cell-5" align="left">A finely fibrillar collagen, dispersed with marked oedema</td>
              <td id="table-cell-6" align="left">The juxta-epithelial area shows early hyalinization</td>
              <td id="table-cell-7" align="left">The collagen is moderately hyalinized</td>
              <td id="table-cell-8" align="left">The collagen is completely hyalinized</td>
            </tr>
            <tr id="table-row-3">
              <td id="table-cell-9" align="left">The fibroblastic response is strong</td>
              <td id="table-cell-10" align="left">Plump young fibroblasts are present in moderate numbers</td>
              <td id="table-cell-11" align="left">The fibroblastic response is less marked, the cells present being mostly adult fibrocytes</td>
              <td id="table-cell-12" align="left">The hyalinized areas are devoid of fibroblasts</td>
            </tr>
            <tr id="table-row-4">
              <td id="table-cell-13" align="left">The blood vessels are sometimes normal, but more often they are dilated and congested</td>
              <td id="table-cell-14" align="left">The blood vessels are dilated and congested</td>
              <td id="table-cell-15" align="left">Blood vessels are normal or constricted</td>
              <td id="table-cell-16" align="left">Blood vessels are completely obliterated or narrowed</td>
            </tr>
            <tr id="table-row-5">
              <td id="table-cell-17" align="left">Inflammatory cells, mainly polymorphonuclear leukocytes with an occasional eosinophil, are present</td>
              <td id="table-cell-18" align="left">Inflammatory cells are mostly mononuclear lymphocytes, eosinophils, and an occasional plasma cell</td>
              <td id="table-cell-19" align="left">Inflammatory exudates consist of lymphocytes and plasma cells, although an occasional eosinophil is seen</td>
              <td id="table-cell-20" align="left">Inflammatory cells are lymphocytes and plasma cells(15)</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p id="p-2a4fb85e74c9">
        <bold id="s-9cbaf69f6212">Investigations in OSMF: </bold>
      </p>
      <list list-type="order">
        <list-item id="li-0eb01425952b">
          <p>Complete Hemogram</p>
        </list-item>
        <list-item id="li-7ddf0c39b32f">
          <p> Toludine blue test</p>
        </list-item>
        <list-item id="li-4cc60eb8cb64">
          <p> Biopsy :- Incisional biopsy</p>
        </list-item>
        <list-item id="li-13297a111e64">
          <p>Immunofluorescent test: </p>
        </list-item>
      </list>
      <p id="p-8ec90f552551">(a) Direct </p>
      <p id="p-8613915cc92c">(b)Indirect </p>
      <p id="p-f39c6be24af2"><bold id="s-e9e45492941e">Management of OSMF:</bold> </p>
      <p id="p-a00414eb68a5">Eliminating causative agents is part of the management of submucous fibrosis. Therapeutic measures include local injections of chymotrypsin, hyaluronidase, and dexamethasone, with surgical excision of fibrous bands and submucosal</p>
      <p id="p-67b1e367e951">placement of vascularized free flap grafts. All methods of treatment, including surgical modalities, however, have proved to be of only modest help in this essentially irreversible condition.</p>
      <list list-type="order">
        <list-item id="li-e6b9e13b8a30">
          <p>
            <bold id="s-661b4b39b814">Lifestyle Changes:</bold>
          </p>
        </list-item>
      </list>
      <p id="p-422871d60cd2">Avoid areca nut &amp; other chronic irritant such as hot and spicy food.</p>
      <p id="p-151880fd1ade">Advice green leafy vegetables.</p>
      <p id="p-e60f68d6668a">Intake of Vit. A, B complex rich diet &amp; high protein diet.</p>
      <p id="p-2efc100ff1ef">Minimizing consumption of spicy foods, including chiles.</p>
      <p id="p-b58382ce73d9">Maintaining proper oral hygiene.</p>
      <p id="p-4cdc445fcbaf">Avoid hot fluids like tea, coffee</p>
      <p id="p-51c01a9309c1">Avoid alcohol</p>
      <p id="p-4dc42a4fda69">
        <bold id="s-d32b4ee0c3cb">2. Physiotherapy:</bold>
      </p>
      <p id="p-4dda06b253cc">It includes forceful mouth opening , repeated blooming of balloons ,heat therapy.</p>
      <p id="p-585e314cc124">
        <bold id="s-d70ff79e3445">3. Medical Management:</bold>
      </p>
      <p id="p-519f634b7468"><italic id="emphasis-1"><bold id="s-3e9302b6f885">Steroids</bold>:</italic> In patients with moderate OSF, sub mucosal intralesional injections given. Topical application of steroids may help, prevent further damage. The recommended dose is 75 to 100 mg twice a week for 4 to 6 weeks.</p>
      <p id="p-1f041de9c4a4"><italic id="emphasis-2"><bold id="s-6844a5370554"> </bold></italic><bold id="s-6844a5370554-1450ed24-698f-42de-a5a5-de1d8587908b"><italic id="emphasis-3">Placental extracts:</italic> </bold>Sur in 2003 reported that the rationale for using placental extract (PE) in patients with OSMF derives from its proposed anti-inflammatory effect prevents the mucosal damage.<xref id="x-090bc0d8a79d" rid="R87116520196363" ref-type="bibr">16</xref>  Recommended dose of placental extract is 2ml twice weekly for 4 to 6 weeks.</p>
      <p id="p-1a619e9a7e5a"><italic id="emphasis-4"> </italic><italic id="emphasis-5"><bold id="s-99e26724c061">Hyaluronidase:</bold></italic><bold id="s-99e26724c061-9e6eed24-9ffd-433d-a9d3-6a35f5503d48"> </bold>The use of topical hyaluronidase shows significant improvement than steroids alone. The recommended dose is 1500 i.u twice weekly for 4 to 6 weeks. According to Karkar in 1985 the combination of steroids and topical hyaluronidase showed better long-term results than either used alone.<xref id="x-47663e953297" rid="R87116520196364" ref-type="bibr">17</xref> </p>
      <p id="p-33c76392905e"><italic id="emphasis-6"><bold id="s-370895445177">IFN-gamma:</bold></italic> It plays a role in the treatment of patients with OSMF because of its immunoregulatory effect. IFN-gamma</p>
      <p id="p-304a889b2d25">is a known antifibrotic cytokine. <xref id="x-f6537e99625b" rid="R87116520196365" ref-type="bibr">18</xref></p>
      <p id="p-06f0c9258cc4"><italic id="emphasis-9"><bold id="s-093632107d29">Supplements:</bold></italic> Administration of Antoxidants OD for 6 – 8 weeks.</p>
      <p id="paragraph-27">Administration of Lycopene OD for 6-8 weeks</p>
      <p id="paragraph-28"><bold id="s-a11657802fa6"> 4. Surgical Management:  </bold>Measures such as forcing the mouth open and cutting the fibrotic bands have resulted in more fibrosis and disability. Submucosal resection of fibrotic bands and replacement with a partial thickness skin or mucosal graft have also been attempted along with procedures such as bilateral temporalis myotomy. At a retrospective glance, surgery seems to be a poor option in the overall management of the disease.<xref id="x-eee995c96a4d" rid="R87116520196355" ref-type="bibr">8</xref> </p>
      <p id="p-93f7af89beb2">Surgical treatment is indicated in patients with severe conditions. These include:- <bold id="s-1160eb6381be"/></p>
      <p id="paragraph-30"><italic id="emphasis-10"><bold id="s-4648c74cd8c5">Simple excision of the fibrous bands:</bold></italic> Excision can result in contracture of the tissue and exacerbation of the condition.</p>
      <p id="paragraph-32"><bold id="s-0db9cb0d24e2"><italic id="emphasis-11">Split-thickness skin grafting following bilateral temporalis myotomy or coronoidectomy:</italic></bold> Trismus associated with OSMF may be due to changes in the temporalis tendon secondary to OSMF; therefore, skin grafts may relieve.<xref id="x-2818dd364dc6" rid="R87116520196366" ref-type="bibr">19</xref> </p>
      <p id="paragraph-33"><bold id="s-4fb0c8664e93"><italic id="emphasis-12">Nasolabial flaps and lingual pedicle flaps:</italic></bold> Surgery performed only in patients with OSMF in whom the tongue is not involved.<xref id="x-9bbad34037fc" rid="R87116520196367" ref-type="bibr">20</xref> </p>
      <p id="p-a10387e0a4f6">5. <bold id="s-d7ae11e97dd3">Home remedies:</bold> Tulsi and turmeric (curcumin) along with life style modification is safe and efficacious remedy for the treatment of all grades of OSMF in all age groups with no limitation to its use. Tulsi and turmeric can provide a safer, low cost, and effective alternative to the present conventional treatment, which can be useful in a country like India.Mix 1 gm of turmeric powder and 1 gm of tulsi powder in glycerine to make a paste. The patients were instructed to apply this paste all over the oral mucosa 4-5 times per day and not to eat or drink anything for next 15 minutes.<xref id="x-c65240da7f53" rid="R87116520196368" ref-type="bibr">21</xref>  Herbal treatment can provide a safer, low cost, and effective alternative to the present conventional treatment, which can be useful in a country like India. Further studies are going on to access the comparative efficacy with already existing treatment for OSMF.</p>
      <p id="p-64c44aff7a3a">6. <bold id="s-f06e91d93e35">Conselling of the patient: </bold>Sometimes a psychological conselling of the patient is required in advance cases of OSMF, as patient thinks they are going to suffer from oral cancer or they are going to die because of this condition. So , family support and social support along with conselling of patient becomes important in some advance cases.</p>
    </sec>
    <sec>
      <title id="t-e81b6c177114">
        <bold id="s-9a0117c00ffe">Conclusion: </bold>
      </title>
      <p id="p-4307ec75a722">OSF is a disease with a high degree of incidence. It also carries a significant morbidity rate from oral cancer<bold id="s-9570abc0df44">.</bold> The treatment of patients with oral submucous fibrosis depends on the degree of clinical involvement. If the disease is detected at a very early stage, cessation of the habit is sufficient. Most patients with oral submucous fibrosis present with moderate-to-severe disease. Severe oral submucous fibrosis is irreversible. Current modern day medical treatments can make the mouth opening to normal minimum levels of 30 mm mouth opening with proper treatment.</p>
      <p id="p-7dc94bcb6715">
        <bold id="s-dec1283edcb7"> </bold>
      </p>
      <p id="p-4ac575f2f48c"/>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="R87116520196348">
        <element-citation publication-type="misc">
          <source>South Indain Jouranl of oral pathology and med</source>
          <year>2004</year>
        </element-citation>
      </ref>
      <ref id="R87116520196349">
        <element-citation publication-type="misc">
          <person-group person-group-type="author">
            <name>
              <surname>Sur</surname>
              <given-names>T K</given-names>
            </name>
            <collab/>
          </person-group>
          <year>2003</year>
        </element-citation>
      </ref>
      <ref id="R87116520196350">
        <element-citation publication-type="misc">
          <person-group person-group-type="author">
            <name>
              <surname>Harvey</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>M</given-names>
            </name>
            <collab/>
          </person-group>
          <year>1986</year>
        </element-citation>
      </ref>
      <ref id="R87116520196351">
        <element-citation publication-type="misc">
          <person-group person-group-type="author">
            <name>
              <surname>Harvey</surname>
              <given-names>W</given-names>
            </name>
            <collab/>
          </person-group>
          <year>1986</year>
        </element-citation>
      </ref>
      <ref id="R87116520196352">
        <element-citation publication-type="misc">
          <person-group person-group-type="author">
            <name>
              <surname>Khanna Ss</surname>
            </name>
            <collab/>
          </person-group>
          <source>Karojdkar FR - circulating immune complexes and trace elements as markers in oral precancer and cancer</source>
          <year>2006</year>
        </element-citation>
      </ref>
      <ref id="R87116520196353">
        <element-citation publication-type="misc">
          <source>Oral submucous fibrosis patients have altered levels of cytokine production , journal of oral path ology &amp; med</source>
          <year>2009</year>
        </element-citation>
      </ref>
      <ref id="R87116520196354">
        <element-citation publication-type="misc">
          <source>Shaefer’s Textbook of oral path</source>
        </element-citation>
      </ref>
      <ref id="R87116520196355">
        <element-citation publication-type="misc">
          <person-group person-group-type="author">
            <name>
              <surname>Sheil</surname>
              <given-names>T Y</given-names>
            </name>
            <collab/>
          </person-group>
          <year>1992</year>
        </element-citation>
      </ref>
      <ref id="R87116520196356">
        <element-citation publication-type="journal">
          <article-title>OSMF: A review</article-title>
          <source>Australian dent journal</source>
          <year>1996</year>
          <fpage>0</fpage>
          <lpage>0</lpage>
        </element-citation>
      </ref>
      <ref id="R87116520196357">
        <element-citation publication-type="misc">
          <person-group person-group-type="author">
            <name>
              <surname>Gupta Pc</surname>
            </name>
            <collab/>
          </person-group>
          <year>1996</year>
        </element-citation>
      </ref>
      <ref id="R87116520196358">
        <element-citation publication-type="misc">
          <source>Oral pathology- clinical Pathological Co-relations</source>
          <year>2016</year>
          <publisher-name>Elseiveir</publisher-name>
        </element-citation>
      </ref>
      <ref id="R87116520196359">
        <element-citation publication-type="misc">
          <source>Clinical evaluation of the role of Tulsi &amp; Turmeric in management of oral submucous fibrosis ,journal of Ayurveda &amp; intergrative medicine</source>
        </element-citation>
      </ref>
      <ref id="R87116520196360">
        <element-citation publication-type="misc">
          <person-group person-group-type="author">
            <name>
              <surname>Meghji</surname>
              <given-names>S</given-names>
            </name>
            <collab/>
          </person-group>
          <year>1987</year>
        </element-citation>
      </ref>
      <ref id="R87116520196361">
        <element-citation publication-type="misc">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>J - Idiopathica Mucosae</given-names>
            </name>
            <name>
              <surname>Oris</surname>
            </name>
            <collab/>
          </person-group>
          <year>1952</year>
        </element-citation>
      </ref>
      <ref id="R87116520196362">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joshi</surname>
              <given-names>S G</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Fibrosis of palate</article-title>
          <source>Indian journal of otolaryngology</source>
          <year>1953</year>
        </element-citation>
      </ref>
      <ref id="R87116520196363">
        <element-citation publication-type="misc">
          <source>Oral submucous fibrosis - an update</source>
          <year>2015</year>
        </element-citation>
      </ref>
      <ref id="R87116520196364">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burkett</surname>
              <given-names>’</given-names>
            </name>
            <collab/>
          </person-group>
          <source>Oral Medicine</source>
        </element-citation>
      </ref>
      <ref id="R87116520196365">
        <element-citation publication-type="misc">
          <person-group person-group-type="author">
            <name>
              <surname>Pindborj Jj</surname>
              <given-names>Osmf - A</given-names>
            </name>
            <name>
              <surname>Review</surname>
            </name>
            <collab/>
          </person-group>
          <year>1989</year>
        </element-citation>
      </ref>
      <ref id="R87116520196366">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seedat</surname>
              <given-names>H A</given-names>
            </name>
            <name>
              <surname>Van Wyk</surname>
            </name>
            <collab/>
          </person-group>
          <article-title>CW - betel nut chewing &amp; OSF in Durban S</article-title>
          <source>African Med journal</source>
          <year>1988</year>
        </element-citation>
      </ref>
      <ref id="R87116520196367">
        <element-citation publication-type="misc">
          <person-group person-group-type="author">
            <name>
              <surname>Aziz</surname>
              <given-names>S R</given-names>
            </name>
            <collab/>
          </person-group>
          <source>Oral submucous fibrosis - an unusual disease</source>
        </element-citation>
      </ref>
      <ref id="R87116520196368">
        <element-citation publication-type="misc">
          <person-group person-group-type="author">
            <name>
              <surname>Kakkar</surname>
              <given-names>P K</given-names>
            </name>
            <collab/>
          </person-group>
          <source>Puri RK - oral submucous fibrosis treatment with hyalase , journal of laryngology otology</source>
          <year>1985</year>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
